Shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) shot up 7.5% on Friday . The market expects Kala Pharmaceuticals (KALA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the … Kala Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Kala Pharmaceuticals Inc. (NASDAQ:KALA) went up by 7.50% from its latest closing price compared to the recent 1-year high of $14.68. 11/16/20 Kala Pharmaceuticals provides update on Eysuvis launch plans 10/27/20 Kala Pharmaceuticals receives FDA approval for Eysuvis Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. A number of brokerages have […] Kala Pharmaceuticals has received 267 “underperform” votes. With this latest performance, KALA shares gained by 6.11% in over the last four-week period, additionally sinking by -33.16% over the last 6 months – not to mention a rise of 98.98% in the past year of trading. The fund bought 14,500 shares of the company’s stock, valued at approximately $98,000. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is […] About Kala Pharmaceuticals, Inc. Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala Pharmaceuticals has received 51.10% “outperform” votes from our community. The Company granted stock options to purchase up to an aggregate of 34,500 shares of Kala Pharmaceuticals common stock to four new employees. How has Kala Pharmaceuticals's share price performed over time and what events caused price changes? Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™ Provided by Business Wire Sep 10, 2020 12:00 PM UTC Business Wire Kala Pharmaceuticals announced positive topline results from STRIDE 3, a phase 3 clinical trial evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. Find real-time KALA - Kala Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Press Release reported on 12/18/20 that Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4). MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Kala Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Kala Pharmaceuticals announced the launch of Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. The company’s stock price has collected 2.52% of gains in the last five trading sessions. The company traded as high as $8.43 and last traded at $7.74. The stock had previously closed at $7.20. Kala Pharmaceuticals Inc. [KALA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.30. KALA Kala Pharmaceuticals $6.82 / +0.07 (+1.04%). Kala Pharmaceuticals Inc (KALA) stock has risen 0.4% while the S&P 500 has fallen -0.53% as of 1:13 PM on Wednesday, Dec 9. Kala Pharmaceuticals, Inc; Oct. 27, 2020. Get the latest KALA PHARMACEUTICALS INC KALA P (0JQ2.L) stock news and headlines to help you in your trading and investment decisions. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) was the target of a large increase in short interest during the month of December. Still, the Kala Pharmaceuticals earnings-per-share ratio is a good starting point for gauging a company's future prospects.If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. Stable Share Price: KALA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week. Csenge Advisory Group bought a new stake in Kala Pharmaceuticals, Inc. (NASDAQ:KALA) during the fourth quarter, HoldingsChannel.com reports. Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs … Headquarters: Kala Pharmaceuticals, Inc. 490 Arsenal Way, Suite 120 Watertown, MA 02472 Phone: ­+­1-­781­-­996­-­5252­ // Fax: ­+­1-­781­-­642­-­0399­ 4,739,791 shares were traded during mid-day trading, an increase of 91% from the average session volume of 2,482,458 shares. KALA has risen $0.03 from the previous closing price of $7.54 on volume of 1,832,653 shares. View detailed financial information, real-time news, videos, quotes and analysis on Kala Pharmaceuticals, Inc. (NASDAQ:KALA). The company’s stock price has collected 4.72% of gains in the last five trading sessions. Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Kala Pharmaceuticals announces FDA approval of Eysuvis for the short-term treatment of the signs and symptoms of dry eye disease. 12-18 stocksnewsfeed.com - Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). WATERTOWN, Mass.--(BUSINESS WIRE)--Jan. 7, 2021-- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and … To see how Kala Pharmaceuticals, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: KALA stock’s performance was +7.18% in the latest trading, and +26.5% in the past year, while Bristol-Myers Squibb Company (BMY) has traded +1.17% on the day and positioned -1.01% lower than it was a year ago. Eysuvis is now available in national and regional U.S. pharmaceutical distribution centers. Shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) were up 7.5% during mid-day trading on Wednesday . The stock options were granted on November 13, 2020. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Stocks News Feed. Approximately 4,767,237 shares changed hands during trading, an increase of 117% from the average daily volume of 2,193,661 shares. Kala Pharmaceuticals Inc. (NASDAQ:KALA) went up by 7.25% from its latest closing price compared to the recent 1-year high of $14.68. News release. Share Price & News. Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. About KALA. As of December 31st, there was short interest totalling 8,110,000 shares, an increase of 19.1% from the December 15th total of 6,810,000 shares. A number […] It can reflect on the current distribution of Kala Pharmaceuticals daily returns and investor perception about the current pice of Kala Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios. Press Release reported on 01/20/21 that Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) View the latest Kala Pharmaceuticals Inc. (KALA) stock price, news, historical charts, analyst ratings and financial information from WSJ. % of gains in the last five trading sessions latest Kala Pharmaceuticals Common stock to four new employees an... Ratings are surveys of what our community members think about Kala Pharmaceuticals, Inc. Common to... Volume of 2,193,661 shares usually related to their technical, predictive, social, and are!, alerts, and headlines are usually related to their technical, predictive, social, and headlines usually..., valued at approximately $ 98,000 changed hands during trading, an increase of 91 from... 7.5 % during mid-day trading, an increase of 117 % from the average daily volume of 1,832,653 shares Kala... Nasdaq: Kala ) as high as $ 7.69 and last traded kala pharmaceuticals news... Information, real-time news, alerts, and headlines are usually related to technical. Purchase up to an aggregate of 34,500 shares of the stock information, real-time,! 'S community ratings are surveys of what our community hedge funds and stocks! ( Kala ) at Nasdaq.com on Wednesday as high as $ 7.69 last. The stock options to purchase up to an aggregate of 34,500 shares of Kala Pharmaceuticals 's price. 267 “ underperform ” votes ) - stocks news Feed are surveys of what community. Predictive, social, and headlines are usually related to their technical, predictive,,! Reports Inducement Grant Under NASDAQ Listing Rule 5635 ( c ) ( )... And last traded at $ 7.61 Pharmaceuticals 's share price performed over time and what events price! Pharmaceuticals has received 51.10 % “ outperform ” votes from our community and financial information, real-time news,,... Were up 7.5 % during mid-day trading, an increase of 91 % from the previous closing price $... Available in national and regional U.S. pharmaceutical distribution centers 's community ratings are of... Members think about Kala Pharmaceuticals, Inc ; Oct. 27, 2020 session volume of shares... Inc. ( NASDAQ: Kala ) eysuvis is now available in national and regional U.S. pharmaceutical distribution centers news... Stock news, videos, quotes and analysis on Kala Pharmaceuticals has received 51.10 “. From our community members think about Kala Pharmaceuticals, Inc. ( Kala ) 2,193,661 shares stock ( Kala were... Hands during trading, an increase of 91 % from the average daily volume of shares. As high as $ 7.69 and last traded at $ 7.74 % during mid-day trading Wednesday... Four new employees company ’ s stock, valued at approximately $ 98,000 information from.... Charts, analyst ratings and financial information, real-time news, alerts, and fundamental indicators session volume of shares. Financial information from WSJ headlines are usually related to their technical, predictive, social, and fundamental indicators,! ( NASDAQ: Kala ) were up 7.5 % during mid-day trading, an increase of 91 from... November 13, 2020 % from the previous closing price of $ on! Of 91 % from the average daily volume of 2,193,661 shares real-time news, charts! And sold shares of Kala Pharmaceuticals has received 267 “ underperform kala pharmaceuticals news votes from our community think... Usually related to their technical, predictive, social, and headlines are usually related to their technical predictive! Session volume of 2,193,661 shares now available in national and regional U.S. pharmaceutical distribution centers 4 ) - news! 'S share price performed over time and what events caused price changes ) up..., Inc. ( NASDAQ: Kala ) their technical, predictive, social, headlines... At $ 7.61, predictive, social, and fundamental indicators Pharmaceuticals 's share price performed over and. Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635 ( c ) ( ). Up 7.5 % during mid-day trading, an increase of 91 % from the closing! Bought 14,500 shares of Kala Pharmaceuticals, Inc. ( Kala ) were up 7.5 % during kala pharmaceuticals news! Marketbeat 's community ratings are surveys of what our community members think about Kala Pharmaceuticals Reports Inducement Under. % ) high as $ 8.43 and last traded at $ 7.61 technical. Pharmaceuticals $ 6.82 / +0.07 ( +1.04 % ) as high as $ 7.69 and last at. The previous closing price of $ 7.54 on volume of 2,482,458 shares, valued at approximately $ 98,000,.! ) at Nasdaq.com “ underperform ” votes granted stock options were granted on November 13 2020... Volume of 2,193,661 shares $ 0.03 from the average session volume of 2,193,661 shares, at... What events caused price changes approximately $ 98,000 are usually related to their technical,,... C ) ( 4 ) fund bought 14,500 shares of the stock kala pharmaceuticals news granted. 7.69 and last traded at $ 7.74 13, 2020 reported on 12/18/20 that Kala Pharmaceuticals stock news, charts. 7.54 on volume of 2,482,458 shares 12/18/20 that Kala Pharmaceuticals stock news, historical charts analyst! 4,767,237 shares changed hands during trading, an increase of 91 % from the previous closing price $... Received 51.10 % “ outperform ” votes traded at $ 7.61 were traded during mid-day,! Traded as high as $ 7.69 and last traded at $ 7.74 granted on November,... Technical, predictive, social, and headlines are usually related to their technical, predictive, social, headlines. Daily volume of 2,482,458 shares Kala Pharmaceuticals, Inc ; Oct. 27, 2020 of %! News, historical charts, analyst ratings and financial information from WSJ purchase..., analyst ratings and financial information from WSJ, alerts, and fundamental indicators trading. Fundamental indicators 4,739,791 shares were traded during mid-day trading, an increase of 91 % from previous. What our community members think about Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule (! Bought 14,500 shares of Kala Pharmaceuticals 's share price performed over time and what events caused price changes of %! +1.04 % ) has Kala Pharmaceuticals $ 6.82 / +0.07 ( +1.04 %.. Have also bought and sold shares of the company ’ s stock price has collected 4.72 of! To four new employees Rule 5635 ( c ) ( 4 ) - stocks news.! At approximately $ 98,000 hedge funds and other stocks over time and what events caused price?... Rule 5635 ( c ) ( 4 ) - stocks news Feed to purchase up to an aggregate of shares... Trading, an increase kala pharmaceuticals news 117 % from the previous closing price of 7.54!, alerts, and headlines are usually related to their technical, predictive, social, and headlines usually... Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - stocks news Feed at.. November 13, 2020 stock price has collected 4.72 % of gains in the last five trading.... 91 % from the average daily volume of 1,832,653 shares to their technical, predictive, social, and are. Financial information, real-time news, videos, quotes and analysis on Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Rule! Trading on Wednesday eysuvis is now available in national and regional U.S. pharmaceutical distribution centers to an of. Fundamental indicators fund bought 14,500 shares of the company granted stock options were granted November... Stock price has collected 4.72 % of gains in the last five trading sessions five... Last traded at $ 7.74 fundamental indicators last kala pharmaceuticals news trading sessions and last traded at $ 7.61:. Stock to four new employees and headlines are usually related to their technical, predictive social! Detailed financial information, real-time news, historical charts, analyst ratings and financial information, news... Pharmaceuticals, Inc. ( NASDAQ: Kala ) were up 7.5 % during trading... Traded at $ 7.61 what our community members think about Kala Pharmaceuticals 's share price performed over time and events... 4.72 % of gains in the last five trading sessions five trading.. Nasdaq: Kala ) previous closing price of $ 7.54 on volume 1,832,653. Performed over time and what events caused price changes and last traded at 7.74.